challenges with measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
Published 7 years ago • 87 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:18
the utility of measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
4:30
measurable residual disease in aml
-
2:51
mrd testing in acute leukemias
-
1:35
the role of mrd in aml
-
9:03
iccs education: minimal/measurable residual disease testing (mrd) by flow cytometry in bll
-
3:07
minimal residual disease (mrd)
-
56:44
40 years of mrd. a review of flow cytometry as an advanced technique for b-all monitoring
-
1:39
how can mrd guide treatment of aml?
-
2:35
mrd focus: why measurable residual disease testing is the future
-
1:26
the current role of mrd in aml and challenges with implementing this in clinical practice
-
0:56
overcoming the challenges in prolonging remission in aml
-
1:50
the possibility of using mrd status to drive treatment in aml
-
2:36
mrd testing in aml: the next steps in 2019
-
3:05
mrd negativity assessed by flow cytometry associated with improved outcomes in npm1-mutated aml
-
1:09
pre-measure: patients with aml in complete remission but high risk of relapse following allohct
-
2:02
measuring mrd: methods and challenges
-
1:32
methods to evaluate mrd in aml
-
2:27
how to utilize mrd testing for aml
-
2:04
novel techniques being used for mrd assessment in aml & the importance of considering oligoclonality
-
0:48
pre-measure study: assessing the role of ngs mrd in patients with aml receiving sct
-
1:44
how mrd assessment can inform treatment decisions in aml